PDF herunterladen
Thromb Haemost 1995; 74(02): 722-729
DOI: 10.1055/s-0038-1649804
Original Article
Fibrinolysis
Schattauer GmbH Stuttgart

Native and Non-glycosylated Recombinant Single-chain Urokinase-type Plasminogen Activator Are Recognized by Different Receptor Systems on Rat Parenchymal Liver Cells

Marieke E van der Kaaden
1   The Division of Biopharmaceutics, Sylvius Laboratory, Leiden/Amsterdam Center for Drug Research, University of Leiden, Leiden, The Netherlands
,
Dingeman C Rijken
2   The Gaubius Laboratory TNO Prevention and Health, Leiden, The Netherlands
,
Eleonore Groeneveld
2   The Gaubius Laboratory TNO Prevention and Health, Leiden, The Netherlands
,
Theo J C van Berkel
1   The Division of Biopharmaceutics, Sylvius Laboratory, Leiden/Amsterdam Center for Drug Research, University of Leiden, Leiden, The Netherlands
,
Johan Kuiper
1   The Division of Biopharmaceutics, Sylvius Laboratory, Leiden/Amsterdam Center for Drug Research, University of Leiden, Leiden, The Netherlands
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 07. November 1994

Accepted 04. April 1995

Publikationsdatum:
06. Juli 2018 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints

Summary

The recognition systems mediating the clearance of glycosylated high molecular weight single-chain urokinase-type plasminogen activator (HMW-scu-PA, produced in human embryonic kidney cells) and recombinant non-glycosylated scu-PA (rscu-PA, produced in E. coli) were analyzed by studying their binding charactaristics to freshly isolated rat parenchymal liver cells.

The binding of 125I-HMW-scu-PA at 4° C was calcium-dependent and of high affinity (Kd = 37.6 nM) and could be inhibited by low molecular weight two-chain u-PA (LMW-tcu-PA) and lactose, but not by the low density lipoprotein receptor-related protein (LRP)-associated 39-kDa protein (RAP), rscu-PA or a mutant form lacking amino acids 11-135 (Delta 125-rscu-PA). Removal of the carbohydrate side chain of HMW-scu-PA by treatment with N-glycosidase F, completely reduced the specific binding to the parenchymal cells and strongly reduced its competition with 125I-HMW-scu-PA in cell binding.

Recombinant scu-PA also bound with high affinity (Kd= 38.7 nM) to the parenchymal liver cells. The binding of 125I-rscu-PA could be competed for by unlabeled rscu-PA while Delta 125-rscu-PA, LMW-tcu-PA or lactose were ineffective. In contrast to HMW-scu-PA, binding of 125I-rscu-PA could be effectively inhibited by RAP (Ki = 1.1 nM), while also its association and degradation, as determined at 37° C, were inhibited by RAP. Pretreatment of the parenchymal cells with proteinase K supplied further evidence for the involvement of two different receptor systems. The binding of rscu-PA was decreased for 91%, while that of HMW-scu-PA showed a decrease of 51%.

It is suggested that native HMW-scu-PA is bound and degraded by the rat parenchymal liver cells via a lectin-like recognition site, while non-glycosylated recombinant scu-PA is bound and degraded by rat parenchymal liver cells via the low density lipoprotein receptor-related protein (LRP). The differences in recognition system for native and recombinant proteins by liver cells suggest that the glycosylation of recombinant proteins, as obtained in mammalian expression systems, can be important for their physiological fate and their pharmacological application.

 

  • References

  • 1 Kasai S, Arimura H, Nishida M, Suyama T. Proteolytic cleavage of singlechain pro-urokinase induces a conformational change which follows activation of the zymogen and reduction of its high affinity for fibrin. J Biol Chem 1985; 260: 12377-12381
    PubMedGoogle Scholar
  • 2 Wijngaards G, Rijken DC, van Wezel AL, Groeneveld E, van der Velden CA M. Characterization and fibrin-binding properties of different molecular forms of pro-urokinase form a monkey kidney cell culture. Thromb Res 1986; 42: 749-760
    CrossrefPubMedGoogle Scholar
  • 3 Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-164
    PubMedGoogle Scholar
  • 4 Eaton DL, Scott RW, Baker JB. Purification of human fibroblast urokinase proenzyme and analysis of its regulation by proteases and protease nexin. J Biol Chem 1984; 259: 6241-6247
    PubMedGoogle Scholar
  • 5 Stump DC, Lijnen HR, Collen D. Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator. J Biol Chem 1986; 261: 17120-17126
    PubMedGoogle Scholar
  • 6 Gurewich V, Pannell R, Louie S, Kelley P, Suddith RL, Greenlee R. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase): a study in vitro and in two animal species. J Clin Invest 1984 73: 1731-1739
    PubMedGoogle Scholar
  • 7 Rijken DC, Binnema DJ, Los P. Specific fibrinolytic properties of different molecular forms of pro-urokinase from a monkey kidney cell culture. Thromb Res 1986; 42: 761-768
    CrossrefPubMedGoogle Scholar
  • 8 Collen D, Zamarron C, Lijnen HR, Hoylaerts M. Activation of plasminogen by pro-urokinase. J Biol Chem 1986; 261: 1259-1266
    PubMedGoogle Scholar
  • 9 Lijnen HR, van Hoef B, Collen D. Comparative kinetic analysis of the activation of human plasminogen by natural and recombinant single-chain urokinase-type plasminogen activator. Biochim Biophys Acta 1986; 884: 402-408
    CrossrefPubMedGoogle Scholar
  • 10 Liu J, Pannell R, Gurewich V. A transitional state of pro-urokinase that has a higher catalytic efficiency against glu-plasminogen than urokinase. J Biol Chem 1992; 267: 15289-15292
    PubMedGoogle Scholar
  • 11 Pannell R, Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986; 67: 1215-1223
    PubMedGoogle Scholar
  • 12 Collen D, de Cock F, Lijnen HR. Biological and thrombolytic properties of proenzyme and active forms of human urokinase. Turnover of natural and recombinant urokinase in rabbits and squirrel monkeys. Thromb Haemost 1984; 52: 24-26
    PubMedGoogle Scholar
  • 13 Spriggs DJ, Stasscn JM, Hashimoto Y, Collen D. Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits. Blood 1989; 73: 1207-1212
    PubMedGoogle Scholar
  • 14 Ueno T, Kobayashi N, Maekawa T. Studies on metabolism of urokinase and mechanism of thrombolysis by urokinase. Thromb Haemost 1979; 42: 885-894
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 15 Kuiper J, Rijken DC, de Munk GA W, van Berkel ThJ C. In vivo and in vitro interaction of high and low molecular weight single-chain urokinase- type plasminogen activator with rat liver cells. J Biol Chem 1992; 267: 1589-1595
    PubMedGoogle Scholar
  • 16 Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi F, Assoian RK. Differentiation-enhanced binding of the aminoterminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 1985; 82: 4939-4943
    CrossrefPubMedGoogle Scholar
  • 17 Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator urokinase. J Cell Biol 1985; 100: 86-92
    CrossrefPubMedGoogle Scholar
  • 18 Nielsen LS, Kellerman GM, Behrendt N, Picone R, Danø K, Blasi F. A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. J Biol Chem 1988; 263: 2358-2363
    PubMedGoogle Scholar
  • 19 Roldan AL, Cubellis MV, Massucci MT, Behrendt N, Lund LR, Danø K, Appella E, Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990; 9: 467-474
    PubMedGoogle Scholar
  • 20 Ploug M, Rønne E, Behrendt N, Jensen AL, Blasi F, Danø K. Cellular receptor for urokinase plasminogen activator. J Biol Chem 1991; 266: 1926-1933
    PubMedGoogle Scholar
  • 21 Appella E, Robinson EA, Ulrich SJ, Stoppelli MP, Corti A, Cassani G, Blasi F. The receptor-binding sequence of urokinase. J Biol Chem 1987; 262: 4437-4440
    PubMedGoogle Scholar
  • 22 Nykjaer A, Petersen CM, Moller B, Jensen PH, Moestrup SK, Holtet TL, Etzerodt M, Thogersen HC, Munch M, Andreasen PA, Gliemann J. Purified a2-macroglobulin receptor/LDL receptor-related protein binds urokinase plasminogen activator inhibitor type-1 complex: Evidence that the a2-macroglobulin receptor mediates cellular degradation of urokinase receptor bound complexes. J Biol Chem 1992; 267: 14543-14546
    PubMedGoogle Scholar
  • 23 Kounnas MZ, Henkin J, Argraves S, Strickland DK. Low density lipoprotein receptor-related protein/α2MR mediates cellular uptake of prourokinase. J Biol Chem 1993; 268: 21862-21867
    PubMedGoogle Scholar
  • 24 Moestrup SK, Holtet TL, Etzerodt M, Thogersen HC, Nykjaer A, Andreasen PA, Rasmussen HH, Sottrup-Jensen L, Gliemann J. α2-macroglobulin- proteinase complexes, PAI-1-plasminogen activator complexes, and receptor associated protein bind to a region of the a2-macroglobulin receptor containing a cluster of eight complement-type repeats. J Biol Chem 1993; 268: 13691-13696
    PubMedGoogle Scholar
  • 25 Ashcom JD, Tiller SE, Dickerson K, Cravens JL, Argraves WS, Strickland DK. The human a2-macroglobulin receptor: identification of a 420-kD cell surface glycoprotein specific for the activated conformation of a2-macroglobulin. J Cell Biol 1990; 110: 1041-1048
    CrossrefPubMedGoogle Scholar
  • 26 Moestrup SK, Gliemann J. Purification of the rat hepatic a2-macroglobulin receptor as an approximately 440-kDa single chain protein. J Biol Chem 1989; 264: 15574-15577
    PubMedGoogle Scholar
  • 27 Herz J, Hamann U, Rogne SM, Myklebost O, Gausepohl H, Stanley KK. Surface location and high affinity for calcium of a 500 kD liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J 1988; 7: 4119-4127
    PubMedGoogle Scholar
  • 28 Strickland DK, Ashcom JD, Williams S, Burgess WH, Migliorini M, Argraves WS. Sequence identity between the α2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J Biol 1990; Chem 265: 17401-17404
    PubMedGoogle Scholar
  • 29 Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL. Opposing effects of apolipoproteins E and C on lipoprotein binding of low density liprotein related protein. J Biol Chem 1990; 265: 10771-10779
    PubMedGoogle Scholar
  • 30 Beisiegel U, Weber W, Bengtsson-Olivecrona G. Lipoprotein lipase enhances the binding of chylomicron remnants to low density lipoprotein receptor-related protein. Proc Natl Acad Sci USA 1991; 88: 8342-8346
    CrossrefPubMedGoogle Scholar
  • 31 Bu G, Williams S, Strickland DK, Schwartz AL. Low density lipoprotein receptor-related protein/α2MR is a hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci USA 1992; 89: 7427-7431
    CrossrefPubMedGoogle Scholar
  • 32 Orth K, Madison EL, Gething MJ, Sambrook JF, Herz J. Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalyzed by means of the low density lipoprotein receptor-related protein/α2-macroglobulin receptor. Proc Natl Acad Sci USA 1992; 89: 7422-7426
    CrossrefPubMedGoogle Scholar
  • 33 Herz J, Clouthier DE, Hammer RE. LDL receptor-related protein internalizes and degrades uPA-PAIl complexes and is essential for embryo implantation. Cell 1992; 71: 411-421
    CrossrefPubMedGoogle Scholar
  • 34 de Munk GA W, Groeneveld E, Rijken DC. Acceleration of the thrombin- inactivation of single-chain urokinase-type plasminogen activator (prourokinase) by thrombomodulin. J Clin Invest 1991; 88: 1680-1684
    CrossrefPubMedGoogle Scholar
  • 35 Orsini G, Brandazza A, Sarmientos P, Molinari A, Lansen J, Cauet G. Efficient renaturation and fibrinolytic properties of prourokinase and a deletion mutant expressed in Escherichia coli as inclusion bodies. Eur J Biochem 1991; 195: 691-697
    CrossrefPubMedGoogle Scholar
  • 36 Herz J, Goldstein JL, Strickland DK, Ho YK, Brown MS. 39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/a2-macroglobulin receptor. J Biol Chem 1991; 266: 21232-21238
    CrossrefPubMedGoogle Scholar
  • 37 Williams SE, Ashcom JD, Argraves WS, Strickland DK. A novel mechanism for controlling the activity of α2-macroglobulin receptor/low density lipoprotein receptor-related protein. J Biol Chem 1992; 267: 9035-9040
    CrossrefPubMedGoogle Scholar
  • 38 Fraker PJ, Speck Jr JC. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. Biochem Biophys Res Commun 1978; 80: 849-857
    CrossrefPubMedGoogle Scholar
  • 39 Seglen PO. Isolation of liver cells. Methods Cell Biol 1976; 13: 29-83
    PubMedGoogle Scholar
  • 40 Casteleyn E, van Rooij HC J, van Berkel ThJ C, Koster JF. Mechanism of glucagon stimulation of fructose-1,6-biphosphatase in rat hepatocytes. Involvement of a low-MRactivator FEBS Lett 1986; 201: 193-197
    CrossrefPubMedGoogle Scholar
  • 41 Lowry OH, Rosebrough NJ, Parr AL, Randall RJ. Protein mcasuremcnl with the f’olin phenol reagent. J Biol Chem 1951; 193: 265-275
    PubMedGoogle Scholar
  • 42 Van Dijk MC M, Kruijt JK, Boers W, Linthorsl C, Van Berkel ThJ C. Distinct properties of the recognition sites for U-very low density lipoprotein (remnant receptor) and -macroglobulin (low density lipoprotein receptor- related protein) on rat parenchymal cells. J Biol Chem 1992; 267: 17732-17737
    PubMedGoogle Scholar
  • 43 Driekamcr K. Two distinct classes of carbohydrate-recognition domains in animal lectins. J Biol Chem 1988; 263: 9557-9560
    PubMedGoogle Scholar
  • 44 Kuiper J, Otter M, van Zonncveld AJ, Rijken DC, van Berkel ThJbC. Tissue-type plasminogen activator and tissue-type plasminogen activator- plasminogen activator inhibitor type-1 complex are recognized by different receptor systems in the liver. Circulation 1993; suppl (Suppl. 04) 2 88: 1-366
    PubMedGoogle Scholar
  • 45 Van Berkel ThJ C, Bihain Bli, Kruijt JK. Blockade of the LDL receptor- related protein by the 39-kI)a protein in rat hcpatocytes leaves the interaction of B-VLDL with the remnant receptor unaffected. Circulation 1993; suppl (Suppl. 04) 2 88: 1-366
    PubMedGoogle Scholar
  • 46 Hajjar KA, Reynolds CM. α-fucose-mediated binding and degradation of tissue-type plasminogen activator by HepG2 cells. J Clin Invest 1994; 93: 703-710
    CrossrefPubMedGoogle Scholar
  • 47 Kenttzer EJ, Buko A, Menon G, Sarin VK. Carbohydrate composition and presence of a liieose-prolein linkage in recombinant human pro-urokinase. Bioehem and Biophis Res Comm 1990; 171: 401-406
    PubMedGoogle Scholar
  • 48 Buko AM, Kentzer EJ, Petros A, Menon G, Zuiderweg MR P, Sarin VK. Characterization of a posttranslalional lucosylation in the growth factor domain of urinary plasminogen activator. Proc Natl Acad Sci USA 1991; 88: 3992-3996
    CrossrefPubMedGoogle Scholar
  • 49 Henkin J, Dudlak D, Beebe DP, Sennello L. High sialic acid content slows prourokinase turnover in rabbits. Thromb Res 1991; 63: 215-225
    CrossrefPubMedGoogle Scholar